Apart from those driver genes mentioned above, other genes such as TP53 (42%), STK11 (29%) and KEAP1/NFE2L2 (27%), also significantly correlate with KRAS mutations (co‐mutation), as suggested in a clinical study which included 330 patients with advanced KRAS‐mutant lung cancers.27 The gene discussed is KRAS; the disease is lung cancer.